GemPharmatech Past Earnings Performance
Past criteria checks 1/6
GemPharmatech has been growing earnings at an average annual rate of 21.9%, while the Life Sciences industry saw earnings growing at 21.9% annually. Revenues have been growing at an average rate of 18.2% per year. GemPharmatech's return on equity is 7.4%, and it has net margins of 24.6%.
Key information
21.9%
Earnings growth rate
9.9%
EPS growth rate
Life Sciences Industry Growth | 26.8% |
Revenue growth rate | 18.2% |
Return on equity | 7.4% |
Net Margin | 24.6% |
Next Earnings Update | 29 Aug 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How GemPharmatech makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Mar 24 | 639 | 157 | 217 | 95 |
31 Dec 23 | 622 | 159 | 209 | 97 |
30 Sep 23 | 585 | 154 | 201 | 97 |
30 Jun 23 | 562 | 161 | 196 | 95 |
31 Mar 23 | 541 | 165 | 187 | 89 |
31 Dec 22 | 517 | 165 | 183 | 83 |
30 Sep 22 | 500 | 168 | 173 | 79 |
30 Jun 22 | 466 | 160 | 165 | 70 |
31 Mar 22 | 433 | 137 | 155 | 62 |
31 Dec 21 | 394 | 125 | 139 | 55 |
31 Dec 20 | 262 | 76 | 83 | 48 |
31 Dec 19 | 193 | 30 | 73 | 30 |
31 Dec 18 | 53 | -6 | 35 | 11 |
Quality Earnings: 688046 has a high level of non-cash earnings.
Growing Profit Margin: 688046's current net profit margins (24.6%) are lower than last year (30.6%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688046's earnings have grown significantly by 21.9% per year over the past 5 years.
Accelerating Growth: 688046's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 688046 had negative earnings growth (-4.9%) over the past year, making it difficult to compare to the Life Sciences industry average (0.7%).
Return on Equity
High ROE: 688046's Return on Equity (7.4%) is considered low.